19 results about "Moxidectin" patented technology

The invention discloses a preparation process of a moxidectin pouring solution. The preparation process comprises the following steps: S1, respectively preparing a moxidectin initial solution and a thickener premixed solution; s2, the moxidectin initial solution and the thickener premixed solution are stirred and mixed uniformly at the temperature of 25-35 DEG C to form a mixture A, the stirring speed is 150-250 rpm, and the mixing time is 10-20 min; s3, adding auxiliary materials into the mixture A, and uniformly mixing to form a mixture B; s4, supplementing the second solvent into the mixture B to the total amount, uniformly mixing, and filtering to obtain a moxidectin pouring solution; the method comprises the following steps: dissolving a moxidectin raw material in a first solvent to obtain a moxidectin initial solution, and synthesizing the moxidectin raw material by using biological catalysis; the first solvent is a nano-emulsion formed after homogenization. According to the preparation method, the solubility of the medicament, the stability of the preparation and the transdermal drug delivery efficiency are improved by improving the solvent system and controlling the process in the preparation process of the moxidectin pouring solution.

A new method of treating a skin disease or condition in a human subject caused by a parasite, particularly Demodex mite infestations that result in demodicosis, with moxidectin. The demodicosis is typically Demodex blepharitis.

The invention discloses a compound fluralana external preparation for dogs, a preparation method and application, belongs to the technical field of veterinary drugs, and solves the problems that an existing preparation is poor in skin surface permeability, a solvent is easy to volatilize, and use experience and drug effect exertion are influenced. The preparation is prepared from the following raw materials: fluralana, moxidectin, ethyl butylacetamidopropionate and N, N-dimethylformamide. The preparation method comprises the following steps: adding N, N-dimethylacetamide, acetone, an auxiliary adjuvant, a transdermal penetration enhancer, an antioxidant and a surface film-forming agent; according to the invention, the combination of the fluralab and the moxidectin can play a synergistic effect and expand an anti-parasitic spectrum so as to achieve an internal and external driving effect; both the fluralab and the moxidectin belong to high-fat-soluble substances, parasites can be quickly repelled and killed by adding novel adjuvant natural parasite expelling ingredients, and meanwhile, the skin permeability can be improved by adding the efficient transdermal penetration enhancer, and the risk that medicine residues are licked by pets is reduced.

The invention discloses a compound fluralab chewable tablet and a preparation method thereof, and relates to the technical field of veterinary drug preparations, the chewable tablet is composed of fluralab, pyrantel and moxidectin solid dispersion constructed by poloxamer 407 / lauryl sodium sulfate (or sodium dodecyl sulfate); preferably, the particle size D50 of the dispersion is 5-30 microns, and D90 is less than or equal to 80 microns. The preparation method comprises the following steps: firstly, dissolving moxidectin in the system to form a clear solution, drying under reduced pressure, and grinding and sieving at low temperature to obtain a dispersed material; premixing with microcrystalline cellulose, then mixing with lactose, adding a disintegrating agent and a lubricating agent, and carrying out prepressing-main pressing two-stage tabletting to obtain the tablet. The system can maintain amorphous distribution of moxidectin in the tablet, the content uniformity and dissolution and acceleration stability are remarkably improved, broad-spectrum synergy is formed by the moxidectin, the fluralasodium and the pyrantel, and the moxidectin tablet is suitable for killing fleas and ticks, treating roundworms and hookworms and preventing canine heart filariasis and tubuloidiasis.

The invention describes an extended-release composition comprising PLGA or PLA polymeric microspheres comprising an isoxazoline, preferably sarolaner, and a macrocyclic lactone, preferably moxidectin, and wherein the composition further comprises at least one pharmaceutically acceptable excipient; and uses thereof.

The present application relates to a kind of compound moxidectin pour-on and its preparation method and application, specifically to a kind of compound moxidectin pour-on, component mass mass fraction ratio includes: 0.1-5 portion moxidectin, 5-30 portion benzimidazole anthelmintic, 30-70 portion solvent, 5-20 portion solubilizer, 0.1-2 portion antioxidant, 10-30 portion transdermal enhancer.The present application not only covers gastrointestinal nematode, tapeworm, fluke and other various parasites, but also has killing or inhibiting effect on larva, worm egg, solve the problem of single component anthelmintic spectrum narrow, specific parasite effect is not good.

The present invention is aimed at a pharmaceutical formulation or composition and a method of manufacture or production thereof, wherein the pharmaceutical composition includes fluralaner, moxidectin and praziquantel for the treatment of parasitic infestations in animals, wherein the composition may be in tablet form, more particularly as a chewable tablet and more preferably as a soft chewable tablet that manages to mask the bitter taste of the active ingredient praziquantel based on an association of bitter taste receptor blockers.

The application discloses the technical field of biology, and particularly discloses application of moxidectin in preparation of a medicine for resisting akawa virus (AKAV) and a preparation method of the medicine.

The invention belongs to the technical field of pharmaceutical analysis methods, and particularly relates to an in-vitro transdermal test method for fluralab and moxidectin in a fluralab moxidectin drop. According to the method, a Franz diffusion cell device is adopted, SD rat skin is taken as simulated skin, a normal saline solution of polyoxyethylene 20 oil ether is taken as a receiving medium, and a high performance liquid chromatography-ultraviolet visible detector is adopted to detect the contents of the flurala and the moxidectin in the receiving medium, so that the accumulated transdermal amount of the flurala and the moxidectin is calculated. The in-vitro transdermal test method disclosed by the invention is simple, rapid, easy to operate and high in universality.

The invention belongs to the technical field of veterinary drugs, and particularly discloses a permeation enhancer-containing fluralan-moxidectin nano drop and a preparation method thereof, the permeation enhancer-containing fluralan-moxidectin nano drop comprises the following components: fluralan, moxidectin, a permeation enhancer, glycosylglycerol, tocopheryl acetate, a cosolvent, modified chitosan, hydroxy acid salt, an antioxidant and the balance of a solvent; the permeation enhancer is prepared from phytosphingosine, beta-caryophyllene and caprylic / capric triglyceride according to the mass ratio of 1 to (0.2 to 2) to (0.2 to 1.8). According to the invention, the fluralan and the moxidectin are taken as active ingredients, and the permeation enhancer, the glycosylglycerol, the tocopheryl acetate, the modified chitosan, the hydroxy acid salt and the antioxidant are added, so that the permeation effect of the fluralan and the moxidectin is effectively improved, the transdermal absorption effect of the fluralan and the moxidectin is remarkably improved, and the stability of the drops is effectively improved.

This invention belongs to the field of veterinary drug technology. Specifically, it discloses a synergistic var. fluoraranil-moxicillin drop containing plant essential oils. The plant essential oils in the drop can disrupt the lipid structure of the parasite's epidermal wax layer, reduce the epidermal barrier function, increase epidermal permeability, and promote the rapid penetration of fluoraranil and moxicillin into the parasite, thereby increasing the drug concentration and shortening the onset time. At the same time, it also helps to enhance the effect of transdermal penetration enhancers. Fluoraranil acts on the parasite's GABA-gated chloride ion channels, moxicillin acts on the parasite's neuromuscular junction, and the plant essential oil exerts its insecticidal effect by disrupting the parasite's cell membrane integrity and inhibiting its metabolic enzyme activity. The three have different targets and no cross-resistance. They can synergistically block the key survival links of parasites, significantly improve the insecticidal rate, and delay the development of parasite resistance to single drugs.

The invention belongs to the technical field of industrial microbial fermentation process optimization, and discloses a bulk drug production strain culture method based on morphology and physiological parameters. According to the method, through dual verification of physiological trend and form peak, the misjudgment risk of single parameter judgment is avoided, meanwhile, the trend is captured as soon as possible through change rate analysis, and transplanting can be conducted at the golden moment when the thallus activity reaches the peak but does not decline. By quantifying morphology and setting a clear threshold value, human subjective factors are eliminated, the process reproducibility is extremely high, the principle of the method is suitable for production of raw material medicines fermented by various filamentous bacteria, such as acarbose, moxidectin and tobramycin, and finally accurate seed transfer is realized, so that the fermentation period is effectively shortened, the yield of the raw material medicines is improved, and the method is suitable for industrial production. And remarkable economic benefits are brought.

The invention describes an extended-release composition comprising PLGA or PLA polymeric microspheres comprising an isoxazoline, preferably sarolaner, and a macrocyclic lactone, preferably moxidectin, and wherein the composition further comprises at least one pharmaceutically acceptable excipient; and uses thereof.

The present invention relates to microparticles containing moxidectin, and a preparation method thereof. Unlike conventional heartworm prevention drugs that have a short half-life and thus require daily or monthly administration, moxidectin is continuously released for at least three months and thus the effect of preventing heartworms can be maintained for at least three months when the microparticles containing moxidectin are administered. In addition, microparticles which have a constant average diameter and a narrow diameter distribution are prepared so that initial over-release of moxidectin is prevented when the microparticles are administered, the release of the drug can be controlled to keep constant the concentration of moxidectin that is valid for at least three months, and foreign body sensation and pain can be reduced when the microparticles are applied in the form of an injection.

The present invention relates to microparticles containing moxidectin and a method for preparing same. Unlike conventional drugs for preventing heartworm disease, which have a short half-life and require daily or monthly administration, when the microparticles containing moxidectin are administered, moxidectin is continuously released for 3 months or longer, and thus, a heartworm disease preventive effect can be maintained. In addition, by preparing microparticles having a constant average particle diameter and a narrow diameter distribution width, even when the microparticles are administered, the initial over-release of moxidectin is prevented, and the release of the drug is controlled so that a concentration of moxidectin effective for three months or longer can be kept constant, and when the microparticles are applied as an injection, foreign body sensation and pain can be reduced.

The invention discloses a moxidectin long-acting injection and a preparation method thereof, and belongs to the technical field of biological medicines. The moxidectin long-acting injection takes moxidectin as an active component, and is combined with neutral diacyl ester, phospholipid and an organic solvent to form a low-viscosity pre-preparation. After injection, the preparation is subjected to phase change when encountering body fluid in vivo to form a lyotropic liquid crystal type gel storage cavern, so that slow release of the medicine is realized, the medicine effect is remarkably prolonged, and the administration frequency is reduced. The preparation is good in needle passing performance, high in biocompatibility, simple in preparation process and suitable for industrial production, and can be effectively used for long-term prevention and treatment of pet parasites.

The present invention is aimed at a pharmaceutical formulation or composition and a method of manufacture or production thereof, wherein the pharmaceutical composition includes fluralaner, moxidectin and praziquantel for the treatment of parasitic infestations in animals, wherein the composition may be in tablet form, more particularly as a chewable tablet and more preferably as a soft chewable tablet that manages to mask the bitter taste of the active ingredient praziquantel based on an association of bitter taste receptor blockers.

An injectable pharmaceutical composition comprising an isoxazoline compound of Formula (I), or a salt or N-oxide and moxidectin microspheres and a method of preventing or treating a parasite infestation using the same.

Oral bioavailability of pharmaceutical substances drives drug developers to micronize, or reduce the size of active pharmaceutical ingredients. This invention relates to a novel, solid oral dose form of unmicronized moxidectin and a manufacturing process thereof that explicitly avoids a micronization or size reduction step.